Shares of Enzo Biochem have been flying over the past year due to increased demand for its clinical products, successful patent resolutions and new product introductions, says the company’s president Barry Weiner. Enzo recently pocketed a multi-million dollar settlement from Affymetrix and Weiner expects the successful legal resolutions to continue without disrupting the ongoing business. Weiner also says the harsh winter weather hurt Enzo’s clinical business in the first quarter as fewer patients braved the cold to go to the doctor, yet he expects that to normalize going forward.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
